Evaluation of a 12-week targeted vitamin D supplementation regimen in patients with active inflammatory bowel disease
Copyright © 2017 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved..
BACKGROUND & AIMS: Vitamin D at serum 25(OH)D concentrations above 100 nmol/L is associated with disease remission in patients with IBD, suggesting targeted dosing might be anti-inflammatory. This study aimed to assess the effectiveness, safety and predictors of a 12-week regimen of vitamin D supplementation to achieve such a target in patients with active disease.
METHODS: In a pilot study, patients with active colitis and a serum 25(OH)D concentration <75 nmol/L were prescribed oral liquid vitamin D supplementation over 12 weeks using a specific protocol with dose adjusted 4-weekly to aim for a target level of 100-125 nmol/L.
RESULTS: Five patients each with Crohn's colitis or ulcerative colitis (UC) had mean 25(OH)D concentration 52 (range 27-73 nmol/L). Five reached the targeted level and four 89-95 nmol/L. One withdrew after 4 weeks (88 nmol/L). Target dose was met only in those with BMI <30 kg/m2 and total dose inversely correlated with initial serum 25(OH)D. One patient had developed a high level at 8 weeks (146 nmol/L) and another new hypercalciuria. There were no serious adverse events attributable to the therapy. Clinical disease activity consistently declined, but faecal calprotectin and circulating markers of inflammation did not.
CONCLUSIONS: A specified oral vitamin D regimen successfully and safely achieved target or near-target levels, improved symptom-based activity scores, but did not alter objective measures of intestinal or systemic inflammation. A modified version of this dose-escalating regimen would be suitable for a randomised placebo-controlled trial, but does require regular safety monitoring.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Clinical nutrition (Edinburgh, Scotland) - 37(2018), 4 vom: 01. Aug., Seite 1375-1382 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Garg, Mayur [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1406-16-2 |
|---|
| Anmerkungen: |
Date Completed 21.11.2019 Date Revised 08.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clnu.2017.06.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM273294733 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM273294733 | ||
| 003 | DE-627 | ||
| 005 | 20231225000903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clnu.2017.06.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0911.xml |
| 035 | |a (DE-627)NLM273294733 | ||
| 035 | |a (NLM)28651829 | ||
| 035 | |a (PII)S0261-5614(17)30222-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Garg, Mayur |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of a 12-week targeted vitamin D supplementation regimen in patients with active inflammatory bowel disease |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.11.2019 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved. | ||
| 520 | |a BACKGROUND & AIMS: Vitamin D at serum 25(OH)D concentrations above 100 nmol/L is associated with disease remission in patients with IBD, suggesting targeted dosing might be anti-inflammatory. This study aimed to assess the effectiveness, safety and predictors of a 12-week regimen of vitamin D supplementation to achieve such a target in patients with active disease | ||
| 520 | |a METHODS: In a pilot study, patients with active colitis and a serum 25(OH)D concentration <75 nmol/L were prescribed oral liquid vitamin D supplementation over 12 weeks using a specific protocol with dose adjusted 4-weekly to aim for a target level of 100-125 nmol/L | ||
| 520 | |a RESULTS: Five patients each with Crohn's colitis or ulcerative colitis (UC) had mean 25(OH)D concentration 52 (range 27-73 nmol/L). Five reached the targeted level and four 89-95 nmol/L. One withdrew after 4 weeks (88 nmol/L). Target dose was met only in those with BMI <30 kg/m2 and total dose inversely correlated with initial serum 25(OH)D. One patient had developed a high level at 8 weeks (146 nmol/L) and another new hypercalciuria. There were no serious adverse events attributable to the therapy. Clinical disease activity consistently declined, but faecal calprotectin and circulating markers of inflammation did not | ||
| 520 | |a CONCLUSIONS: A specified oral vitamin D regimen successfully and safely achieved target or near-target levels, improved symptom-based activity scores, but did not alter objective measures of intestinal or systemic inflammation. A modified version of this dose-escalating regimen would be suitable for a randomised placebo-controlled trial, but does require regular safety monitoring | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Cholecalciferol | |
| 650 | 4 | |a Colitis | |
| 650 | 4 | |a Crohn's disease | |
| 650 | 4 | |a Inflammatory bowel diseases | |
| 650 | 4 | |a Ulcerative colitis | |
| 650 | 4 | |a Vitamin D | |
| 650 | 7 | |a Vitamin D |2 NLM | |
| 650 | 7 | |a 1406-16-2 |2 NLM | |
| 700 | 1 | |a Rosella, Ourania |e verfasserin |4 aut | |
| 700 | 1 | |a Rosella, Gennaro |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Yunqiu |e verfasserin |4 aut | |
| 700 | 1 | |a Lubel, John S |e verfasserin |4 aut | |
| 700 | 1 | |a Gibson, Peter R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical nutrition (Edinburgh, Scotland) |d 1982 |g 37(2018), 4 vom: 01. Aug., Seite 1375-1382 |w (DE-627)NLM08284366X |x 1532-1983 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2018 |g number:4 |g day:01 |g month:08 |g pages:1375-1382 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clnu.2017.06.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2018 |e 4 |b 01 |c 08 |h 1375-1382 | ||